Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 05 Feb 2026 | Alexandr Hobza Cabinet member | Exchange of views on the structural difficulties of small and medium-sized enterprises (SMEs) in the antibiotics sector in accessing finance to innovate and commercialise, and how EU instruments can better support them. | — |
| 05 Feb 2026 | Alexandr Hobza Cabinet member | Exchange of views on the structural difficulties of small and medium-sized enterprises (SMEs) in the antibiotics sector in accessing finance to innovate and commercialise, and how EU instruments can better support them. | SRC |
| 02 Dec 2025 | Boriša Falatar Cabinet member | MCM strategy | — |
| 02 Dec 2025 | Boriša Falatar Cabinet member | MCM strategy | SRC |
| 14 Nov 2025 | Annukka Ojala Cabinet member | Europe’s health preparedness | — |
| 14 Nov 2025 | Annukka Ojala Cabinet member | Europe’s health preparedness | SRC |
| 26 Sept 2025 | Ann-Sofie Ronnlund Cabinet member | EU innovation policy and Horizon Europe | — |
| 26 Sept 2025 | Alexandra Hild Cabinet member | EU innovation policy and Horizon Europe | SRC |
| 26 Sept 2025 | Ann-Sofie Ronnlund Cabinet member | EU innovation policy and Horizon Europe | SRC |
| 08 Jun 2023 | Pierre Delsaux Director-General | Discussions on push incentives models for antibiotics | — |
| 08 Jun 2023 | Pierre Delsaux Director-General | Discussions on push incentives models for antibiotics | SRC |
| 29 Jun 2022 | Annukka Ojala Cabinet member | VTC meeting on Revision of the pharmaceutical legislation and Anti-microbial resistance. | SRC |
| 29 Jun 2022 | Annukka Ojala Cabinet member | VTC meeting on Revision of the pharmaceutical legislation and Anti-microbial resistance. | — |
| 18 Jan 2022 | Pierre Delsaux Director-General | To discuss HERA | SRC |
| 18 Jan 2022 | Pierre Delsaux Director-General | To discuss HERA | — |
| 01 Oct 2020 | Annukka Ojala Cabinet member | Virtual meeting about the Antimicrobial Resistance | — |
| 01 Oct 2020 | Annukka Ojala Cabinet member | Virtual meeting about the Antimicrobial Resistance | SRC |
| 11 Sept 2020 | Eszter Batta Cabinet member | Challenges faced by EU SME in the anti-microbial resistance field and the upcoming pharmaceutical strategy. | SRC |
| 11 Sept 2020 | Eszter Batta Cabinet member | Challenges faced by EU SME in the anti-microbial resistance field and the upcoming pharmaceutical strategy. | — |
Mission & Goals
Since its inception in 2016, the BEAM Alliance has succeeded in uniting European Small Medium Enterprises (SMEs) working in the field of antimicrobial resistance (AMR). SMEs are recognized as the driving force of today’s innovation in the field of unmet medical need but are facing a now well acknowledged market failure. The BEAM Alliance gives its members a unique voice to propose and support policies and incentives in Europe to fix the market failure. The ultimate goal is to create market conditions attractive enough to pull back the needed support from investors and industrial partners, key stakeholders to bring medicine candidates from R&D stages to the patient. For most stakeholders in the field of AMR (including governments, patients, industry representatives and other policy makers), BEAM is now recognised as a unique contributor helping our understanding of the complex array of cross-disciplinary issues (science, finance, and policymaking).
EU Legislative Interests
The BEAM Alliance is following any legal and regulatory actions intended to improve the current antimicrobial resistance (AMR) market landscape. The BEAM Alliance has thus a special interest in so-called “PULL incentives” that can facilitate the market uptake of innovative solutions against AMR. PULL incentives include financial rewards, improved valuation and pricing methodologies or reimbursement mechanisms. The BEAM Alliance also has a special focus on funding instruments able to de-risk R&D activities (so-called “PUSH incentives”). From a wider perspective, the BEAM Alliance follows all evolutions linked to the fight against AMR (stewardship policies, access to critical medicine, etc.) and more generally policies related to SMEs and innovation. In that regard the BEAM Alliance is interacting with the EU institutions in relation to the following files and policies: EU Action on Antimicrobial Resistance Pharmaceutical Strategy for Europe EU pharmaceutical legislation (Directive 2001/83/EC and Regulation (EC) No 726/2004) Communication on “Building a European Health Union” Europe’s Industrial Strategy SME Strategy EU R&D funding (Horizon 2020, Horizon Europe) Critical Medicines Act Medical Countermeasures Strategy Preparedness Union Communication Lifescience Strategy Startup and scaleup Strategy Biotech Act Innovation Act In Vitro Diagnostic Regulation
Communication Activities
As part of its activities, the BEAM Alliance is in constant interactions with stakeholders involved in the fight against AMR at the international (WHO, UN IACG, European Commission, EMA, ESCMID, EUCAST, Global AMR R&D Hub, etc.) and national (ministries of health) levels. The BEAM Alliance is mainly delivering its vision and propositions through position papers (https://beam-alliance.eu/our-actions/) and invited speakers to conferences and forums, such as the AMR conference (https://amr-conference.com/). The BEAM Alliance is also particularly active during the World Antibiotic Awareness Week (18-24 Nov), and aims at organising roundtables involving stakeholders from different horizons (including European Commission, European Parliament and other national representatives).
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
The BEAM Alliance is a member of the AMR Industry Alliance (https://www.amrindustryalliance.org) and of the AMR Stakeholder Network (https://epha.org/amr-stakeholder-network/)
Organisation Members
The BEAM Alliance has members from 2 types. Full members are private or public pure player SMEs developing products focused upon prevention, diagnosis and cure of microbial infections. Headquarters and main activities are located in Europe. Associated Organizations are private or public actors developing activities against AMR such as services, R&D, etc. The updated list of current members is available here: https://beam-alliance.eu/members/
Connected Legislation